NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Excerpt
This guideline covers identifying, diagnosing and assessing disease severity in adults, children and young people with non-alcoholic fatty liver disease (NAFLD). It also covers both pharmacological and non-pharmacological treatments, disease monitoring and the risk of extra-hepatic conditions associated with NAFLD.
Contents
- Guideline Development Group members
- NGC technical team members
- Co-optees
- Acknowledgements
- 1. Guideline summary
- 2. Introduction
- 3. Development of the guideline
- 4. Methods
- 5. Risk factors for NAFLD
- 6. Diagnosis of NAFLD
- 7. Diagnosing the severity of NAFLD
- 8. Monitoring NAFLD progression
- 8.1. Introduction
- 8.2. Review question: How often should we monitor adults, young people and children with NAFLD or NASH (with or without fibrosis) to determine the risk of disease progression?
- 8.3. Clinical evidence
- 8.4. Economic evidence
- 8.5. Evidence statements
- 8.6
- 8.7. Recommendations and link to evidence
- 9. Extra-hepatic conditions
- 10. Weight reduction interventions
- 10.1. Introduction
- 10.2. Review question: What is the clinical and cost-effectiveness of dietary interventions for weight reduction for adults, young people and children with NAFLD compared with standard care?
- 10.3. Clinical evidence
- 10.4. Economic evidence
- 10.5. Evidence statements
- 10.6. Recommendations and link to evidence
- 11. Dietary modification and supplements
- 11.1. Introduction
- 11.2. Review question: What is the clinical and cost-effectiveness of dietary modifications or supplements for adults, young people and children with NAFLD compared with standard care?
- 11.3. Clinical evidence
- 11.4. Economic evidence
- 11.5. Evidence statements
- 11.6. Recommendations and link to evidence
- 12. Exercise interventions
- 13. Lifestyle modification
- 13.1. Introduction
- 13.2. Review question: What is the clinical and cost-effectiveness of lifestyle modification programmes for diet and exercise interventions for adults, young people and children with NAFLD compared with diet alone, exercise alone or standard care?
- 13.3. Clinical evidence
- 13.4. Economic evidence
- 13.5. Evidence statements
- 13.6. Recommendations and link to evidence
- 14. Alcohol advice
- 15. Fructose advice
- 16. Caffeine advice
- 17. Pharmacological interventions
- 18. Acronyms and abbreviations
- 19. Glossary
- 20. Reference list
- Appendices
- Appendix A. Scope
- Appendix B. Declarations of interest
- Appendix C. Clinical review protocols
- Appendix D. Health economic review protocol
- Appendix E. Clinical article selection
- Appendix F. Health economic article selection
- Appendix G. Literature search strategies
- Appendix H. Clinical evidence tables
- Appendix I. Health Economic evidence tables
- Appendix J. GRADE tables
- Appendix K. Forest plots and diagnostic meta-analysis plots
- Appendix L. Diagnostic meta-analysis
- Appendix M. Excluded clinical studies
- Appendix N. Cost-effectiveness analysis: diagnostic tests for NAFLD and advanced fibrosis
- Appendix O. Unit costs
- Appendix P. Review of economic evidence from NICE public health guidance
- Appendix Q. Research recommendations
- Appendix R. NICE project team
- Appendix S. References
Disclaimer: Healthcare professionals are expected to take NICE clinical guidelines fully into account when exercising their clinical judgement. However, the guidance does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of each patient, in consultation with the patient and, where appropriate, their guardian or carer.
- NLM CatalogRelated NLM Catalog Entries
- Review Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).[Curr Pharm Des. 2020]Review Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).Johnston MP, Patel J, Byrne CD. Curr Pharm Des. 2020; 26(10):1079-1092.
- Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.[Eur J Radiol. 2018]Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.Hui SCN, So HK, Chan DFY, Wong SKH, Yeung DKW, Ng EKW, Chu WCW. Eur J Radiol. 2018 Oct; 107:7-13. Epub 2018 Aug 11.
- Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.[Front Endocrinol (Lausanne). 2...]Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.Guo W, Qin P, Li XN, Wu J, Lu J, Zhu WF, Diao QQ, Xu NZ, Zhang Q. Front Endocrinol (Lausanne). 2021; 12:711956. Epub 2021 Aug 12.
- Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.[J Ultrasound. 2016]Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.Tana C, Tana M, Rossi S, Silingardi M, Schiavone C. J Ultrasound. 2016 Sep; 19(3):183-9. Epub 2016 Mar 29.
- Review Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum.[Proc Nutr Soc. 2019]Review Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum.Fitzpatrick E. Proc Nutr Soc. 2019 Aug; 78(3):362-371. Epub 2019 Feb 8.
- Non-Alcoholic Fatty Liver DiseaseNon-Alcoholic Fatty Liver Disease
Your browsing activity is empty.
Activity recording is turned off.
See more...